About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ARDX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Sep 22, 2026Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to…
NCT05643534 · Irritable Bowel Syndrome With Constipation (IBS-C)
Tenapanor 50 MG, Tenapanor 25 mg bid
ARDX
Ardelyx
Phase 3Completed180Aug 20, 2026Registry ↗
Aug 19, 20264-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
NCT06553547 · Irritable Bowel Syndrome With Constipation (IBS-C)
Tenapanor, Placebo
ARDX
Ardelyx
Phase 2Completed72Jul 7, 2026Registry ↗
Jun 4, 2026A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation i…
NCT07382167 · Chronic Idiopathic Constipation (CIC)
Tenapanor 5 mg BID, Tenapanor 25 mg BID
ARDX
Ardelyx
Phase 3Recruiting692Feb 26, 2027Registry ↗
Jun 4, 2026Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) Wit…
NCT05905926 · Irritable Bowel Syndrome With Constipation (IBS-C)
Tenapanor
ARDX
Ardelyx
Phase 3Enrolling by invitation150Jul 2031Registry ↗
Jul 11, 2024An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating…
NCT06203444 · Lactation
Tenapanor
ARDX
Ardelyx
Phase 1Completed7May 30, 2024Registry ↗
Jun 29, 2023A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
NCT03427125 · Hyperphosphatemia
Tenapanor, Placebo
ARDX
Ardelyx
Phase 3Completed1,559Nov 15, 2019Registry ↗
Mar 29, 2023Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
NCT04549597 · Chronic Kidney Disease Requiring Chronic Dialysis, Hyperpho…
Tenapanor
ARDX
Ardelyx
Phase 4Completed333Oct 13, 2021Registry ↗
Mar 29, 2023A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialy…
NCT03988920 · Hyperphosphatemia, End Stage Renal Disease
Tenapanor, Sevelamer Carbonate
ARDX
Ardelyx
Phase 4Completed172Jun 26, 2021Registry ↗
Mar 6, 2023Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
NCT03824587 · Hyperphosphatemia
Tenapanor, Placebo
ARDX
Ardelyx
Phase 2/3Completed236Jul 17, 2019Registry ↗
May 4, 2022A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
NCT04780841 · Hyperkalemia
RDX013, Placebo
ARDX
Ardelyx
Phase 2Completed109Dec 28, 2021Registry ↗
Sep 14, 2020Dose Finding Study to Treat High Phosphate Levels in the Blood.
NCT02081534 · Hyperphosphatemia
AZD1722, Placebo
ARDX
Ardelyx
Phase 2Completed162Nov 2014Registry ↗
Sep 9, 2020A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
NCT02727751 · Constipation Predominant Irritable Bowel Syndrome
Tenapanor
ARDX
Ardelyx
Phase 3Completed312Oct 2017Registry ↗
Aug 10, 2020An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Dise…
NCT02675998 · Hyperphosphatemia
Tenapanor, Placebo
ARDX
Ardelyx
Phase 3Completed219Dec 2016Registry ↗
Aug 10, 2020Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
NCT01764854 · End Stage Renal Disease, Chronic Kidney Disease Stage 5
AZD1722 (in-patient), Placebo (in-patient)
ARDX
Ardelyx
Phase 2Completed88Oct 2013Registry ↗
May 27, 2020A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
NCT01847092 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
AZD1722, Placebo
ARDX
Ardelyx
Phase 2Completed154Mar 2015Registry ↗
Apr 22, 2020A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
NCT02686138 · Constipation Predominant Irritable Bowel Syndrome
Tenapanor, Placebo
ARDX
Ardelyx
Phase 3Completed593Aug 2017Registry ↗
Apr 21, 2020A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of T…
NCT02621892 · Constipation Predominant Irritable Bowel Syndrome
Tenapanor, Placebo
ARDX
Ardelyx
Phase 3Completed606Mar 2017Registry ↗
Apr 8, 2020The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
NCT01923428 · Constipation Predominant Irritable Bowel Syndrome
AZD1722, Placebo
ARDX
Ardelyx
Phase 2/3Completed356Oct 2014Registry ↗
Dec 26, 2019A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hype…
NCT03018067 · Hyperkalemia
RDX227675, Placebo
ARDX
Ardelyx
Phase 2Terminated60May 2017Registry ↗
Oct 15, 2019A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominan…
NCT01340053 · Constipation Predominant Irritable Bowel Syndrome
RDX5791
ARDX
Ardelyx
Phase 2Completed186Dec 2011Registry ↗
Jun 30, 2016Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers
NCT02819687 · Healthy
RDX5791, Placebo
ARDX
Ardelyx
Phase 1Completed80Mar 2011Registry ↗
Jun 10, 2016Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers
NCT02796131 · Healthy
RDX5791, Placebo
ARDX
Ardelyx
Phase 1Completed105Oct 2011Registry ↗
Sep 22, 2015D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects
NCT02226783 · Healthy Volunteers Food Interaction Study
AZD1722 salt tablet, AZD1722 free base tablet
ARDX
Ardelyx
Phase 1Completed37Oct 2013Registry ↗
Sep 22, 2015To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers
NCT02140281 · Healthy Volunteers
Treatment A (cefadroxil alone), Treatment B - AZD1722 follo…
ARDX
Ardelyx
Phase 1Completed71Aug 2014Registry ↗
Sep 22, 2015To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers
NCT02140268 · Healthy Volunteers
Midazolam, AZD1722
ARDX
Ardelyx
Phase 1Completed65Aug 2014Registry ↗
Sep 22, 2015AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study
NCT02063386 · Healthy Volunteers
AZD1722
ARDX
Ardelyx
Phase 1Completed26May 2014Registry ↗
Jan 27, 2015A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722
NCT02346890 · Healthy
AZD1722, Renvela
ARDX
Ardelyx
Phase 1Completed16Apr 2013Registry ↗

27 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:46 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances